Comparative Study of Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV + Men Being Given Tenofovir With FTC, Emtricitabine (TRUVADA), or Without (VIREAD), as Part of Their Antiretroviral Therapy.

Trial Profile

Comparative Study of Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV + Men Being Given Tenofovir With FTC, Emtricitabine (TRUVADA), or Without (VIREAD), as Part of Their Antiretroviral Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2015 Planned End Date changed from 1 Jun 2014 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 30 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top